Technology ID

Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine

Lead Inventor
Semenova, Vera (CDC)
Quinn, Conrad (CDC)
Pohl, Jan (CDC)
Svoboda, Pavel (CDC)
Dalton, Shannon (CDC)
Schiffer, Jarad (CDC)
Soroka, Stephen (CDC)
Therapeutic Areas
Infectious Disease
Development Status
  • Pre-clinical
  • In vitro data available
Lead IC
Bacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection is achieved. Specifically, this invention relates to a screening method for determining protection against B. anthracis infection that involves testing a biological sample for the presence of antibodies to one or more predefined regions of B. anthracis PA. This technology may be important to any bioterrorism defense strategy.
Commercial Applications
  • Novel anthrax vaccines
  • Post-vaccination screening to determine if anthrax protection is achieved
  • Biodefense
Competitive Advantages
  • May require fewer vaccination follow-ups, while present anthrax vaccines require numerous rounds of injections and boosters for full-effectiveness.
  • Identified peptide sequences, representing regions of PA, elicit an immune response in primate and human sera studies.
Licensing Contact:
Mitzelfelt, Jeremiah